ST Pharm
ST Pharm
01
Who we are
02
Our record
03
Newsroom
04
Contact
En
Ko
ST Pharm
Science & Technology
Business Overview
CDMO
Small Molecule
Oligonucleotide
mRNA
CRO
AnaPath Research & Service
R&D
Virtual R&D
Global R&D
About
ST PHARM
Key Members
History
Global Approval
ST Pharm Family
Public
PR (Public Relations)
News room
All
Media Focus
ST PHARM News
IR (Investor Relations)
Stock Information
IR Library
Disclosure Information
IR Materials
Notice
Careers
ESG
Overview
Environmental
Social
Governance
Sitemap
Contact
Linkedin
Public
IR Materials
PR (Public Relations)
News room
All
Media Focus
ST PHARM News
IR (Investor Relations)
Stock Information
IR Library
Disclosure Information
IR Materials
Notice
IR Library
Disclosure Information
IR Materials
Notice
[IR Materials] mRNA Platform Technology
Mar 14, 2023
[Analyst Report] 4Q review: Oligo-driven strength
Feb 17, 2023
[Earnings Summary] ST PHARM 4Q. 2022 Earnings Summary
Feb 17, 2023
[Presentation] ST PHARM IR Preentation (Feb. 2023)
Feb 6, 2023
[Analyst Report] Fundamentals intact despite noise
Jan 16, 2023
[Analyst Report] Value of mRNA platform growing
Dec 16, 2022
[Analyst Report] 3Q disappoints as clients adjust production volume
Nov 1, 2022
[Analyst Report] Forward path clear
Oct 20, 2022
[Analyst Report] OP in line on growing oligonucleotide sales
Aug 11, 2022
[Presentation] ST PHARM IR Presentation (August 2022)
Aug 5, 2022
[R&D Materials] STP0404 POSTER Presentation in CROI 2020
May 26, 2022
[Presentation] ST PHARM mRNA platform
May 20, 2022
[Presentation] ST PHARM IR Presentation (April 2022)
May 9, 2022
[Analyst Report] Focus on where it is headed, not where it is now
Apr 29, 2022
1
of
2